Antisense Oligonucleotides Market

Antisense Oligonucleotides Market

The global antisense oligonucleotides market, valued at USD 5.78 billion in 2025, is projected to reach USD 6.31 billion in 2026 and USD 8.57 billion by 2035, with a 8.0% CAGR during the forecast period 2026 to 2035.

To learn more about this report, request a free sample copy

Since the approval of Vitravene™ (for the treatment of cytomegalovirus retinitis) in 1998, antisense oligonucleotide (ASO) therapies have evolved into a prominent class of therapeutics. In addition to the seven antisense oligonucleotides drugs, based on such molecules, that are commercially available, around 160 candidates are under development. Examples of recently approved antisense therapeutics include (in reverse chronological order) Viltepso™ (duchenne muscular dystrophy, March 2020), Vyondys 53® (duchenne muscular dystrophy, December 2019) and Waylivra® (hereditary transthyretin-mediated (hATTR) amyloidosis, May 2019). Given their ability to target the root cause of diseases, at the protein expression level, these disease-modifying interventions have potential applications across a wide range of therapeutic areas (including but not limited to oncological disorders, neurodegenerative disorders, respiratory disorders, and even certain rare genetic disorders).

Further, recent advances in antisense oligonucleotide chemistry have enabled the development and synthesis of specialized oligonucleotides, having improved safety profiles and better cell targeting capabilities. In fact, these advanced variants of antisense oligonucleotide-based therapeutic candidates are deemed to possess the potential to cater to the unmet need for effective treatment options for diseases that were previously considered difficult to treat.

Presently, several drug developers, along with ASO technology providers, are actively engaged in the development of various antisense therapy candidates. Innovation in this field of research is mostly focused on improving cell targeting ability, target affinity, nuclease resistance, and optimizing toxicity profiles of antisense oligonucleotide candidates. Several big pharma players have also demonstrated interest in antisense oligonucleotide therapeutics and are investing both time and capital in antisense oligonucleotides market. The market has witnessed substantial partnership activity over the last few years.

The activity in this segment of the industry has also attracted the attention of both private and public sector investors / investment funds, which have extended financial support to the initiatives of capable developer companies. Driven by encouraging clinical trial results, the antisense oligonucleotide therapies market is poised to witness healthy market growth as multiple late stage drug candidates are approved and marketed during the forecast period.

Key Drug Developers in Antisense Oligonucleotides Market

Examples of key companies developing antisense oligonucleotides drugs (which have also been profiled in this market report; the complete list of companies is available in the full report) include Antisense Therapeutics, Biogen, Bio-Path Holdings, Ionis Pharmaceuticals, ProQR Therapeutics, Sarepta Therapeutics, Sterna Biologicals and Wave Life Sciences. This antisense oligonucleotides market report includes an easily searchable excel database of all the companies developing antisense oligonucleotide therapeutics, worldwide.

Recent Developments in Antisense Oligonucleotides Market:

Several recent developments have taken place in the field of antisense oligonucleotides market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

• In February 2026, FDA released draft guidance outlining a new approval pathway for personalized genetic medicines, focusing on genome editing and RNA-based methods enabling bespoke therapies such as custom CRISPR treatments.
• In February 2026, Bayer collaborated with Souffle to hightlight updates on antisense oligonucleotide bepirovirsen for chronic hepatitis B.
• In December 2025, University of Cambridge's MRC Toxicology Unit, Department of Biochemistry, AstraZeneca, Cancer Research UK Scotland Institute, and MRC Harwell received a £3.4 million medical research council prosperity partnership grant to research early safety profiles of antisense oligonucleotide therapeutics using new lab models.
• In January 2025, EMA drug approvals outlook highlights growing regulatory traction for antisense oligonucleotides and RNA-based approaches in neurology, particularly for neurodegenerative and neuromuscular diseases with subcutaneous infrequent dosing to reduce treatment burden.

Scope of the Report

The “Antisense Oligonucleotides Market, till 2030” market report features an extensive study on the current market landscape, market size, market share, market forecast, market outlook and future opportunities of the antisense oligonucleotides market. The market research report underlines an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in antisense oligonucleotides market.

In addition to other elements, the market research report includes:

• A detailed assessment of the current market landscape of antisense oligonucleotide therapeutics, providing information on type of antisense molecule (RNA molecule and DNA molecule), ASO generation (first-generation, second-generation, third-generation and next-generation), phase of development (commercial, clinical, preclinical, and discovery stage) of lead candidates, target genes, target disease indications, target therapeutic areas, route of administration (subcutaneous, intravenous, intrathecal, intravitreal and others) and type of therapy (monotherapy, combination therapy and both). In addition, it provides details on drug developer(s), including year of establishment, company size, and location of headquarters.
• Tabulated profiles of prominent antisense oligonucleotide therapeutic developers. Each profile features a brief overview of the company, its financial information (if available), product portfolio, recent developments and an informed future outlook.
• An in-depth analysis of completed, ongoing and planned clinical studies of various antisense oligonucleotide therapeutics, based on the various relevant parameters, such as trial registration year, trial phase, trial recruitment status, enrolled patient population, study design, leading industry sponsors / collaborators (in terms of number of trials conducted), trial focus, target therapeutic area and target genes, highlighting popular indications, popular interventions and regional distribution of trials.
• A detailed analysis of grants that have been awarded to research institutes for antisense oligonucleotide therapeutic projects, in the period between 2017 and 2020 (till September), on the basis of important parameters, such as year of grant award, amount awarded, administering institute center, support period, type of grant application, purpose of grant award, activity code, study section involved, type of recipient organizations and focus area. In addition, it highlights geographical distribution of recipient organizations, popular therapeutic areas, popular funding institute centers, prominent program officers, and popular recipient organizations.  
• An analysis of the partnerships that have been established in the recent past (2016-2020), covering acquisitions and mergers, licensing agreements, product development agreements, research agreements, joint venture agreements and other relevant types of deals.
• A case study on the oligonucleotide contract manufacturers and purification service providers, providing information on the year of establishment, company size, scale of operation, location of headquarters and type of purification method used.

The key objective of antisense oligonucleotides market report is to provide a detailed market analysis in order to estimate the existing market size, market value, statistics and future opportunity for antisense oligonucleotides market during the forecast period. Based on multiple parameters, such as target patient population, likely adoption rate and the annual treatment cost, we have provided informed estimates on the evolution of antisense oligonucleotides market for the forecast period till 2030.

The market report also features the likely distribution of the current and forecasted opportunity across [A] type of antisense molecule (RNA and DNA molecule) [B] different target indications (duchenne muscular dystrophy, spinal muscular atrophy, hereditary transthyretin-mediated (hATTR) amyloidosis, familial chylomicronemia syndrome, familial partial lipodystrophy, pouchitis, leber's congenital amaurosis, huntington’s disease and amyotrophic lateral sclerosis) [C] ASO generations (first-generation, second-generation and third-generation) [D] route of administration (intrathecal, intravenous, intravitreal, subcutaneous biologics, and topical) [E] type of therapy (combination therapy and monotherapy) and [F] key geographical regions (US, UK, EU4, Asia-Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

All actual figures have been sourced and analyzed from publicly available information forums and inputs from primary research. Financial figures mentioned in this market research report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What are antisense oligonucleotide therapeutics?

Answer: Antisense oligonucleotide therapeutics incorporate a single stranded nucleotide molecule, which is complementary to a specific mRNA target. The primary objective of the antisense therapeutics is to downregulate a molecular target or modulate the target gene expression.

Question 2: How big is the antisense oligonucleotides market?

Answer: The antisense oligonucleotides industry size is estimated to be worth $6.31 billion in 2026.

Question 3: What is the projected market growth of the antisense oligonucleotides market?

Answer: The market of antisense oligonucleotides is expected to grow at compounded annual growth rate (CAGR) of 8.0%, till 2030.

Question 4: Who are the leading drug developers in the antisense oligonucleotides market?

Answer: Examples of key companies engaged in developing drugs in the antisense oligonucleotides market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Antisense Therapeutics, Biogen, Bio-Path Holdings, Ionis Pharmaceuticals, ProQR Therapeutics, Sarepta Therapeutics, Sterna Biologicals and Wave Life Sciences.

Question 5: How many drug candidates are currently marketed / under development by companies engaged in the antisense oligonucleotides market?

Answer: Over 200 drug candidates are currently marketed / under development in the antisense oligonucleotides market.

Question 6: How many partnership deals have been inked between the stakeholders engaged in antisense oligonucleotides market?

Answer: Since 2016, more than 60 partnership deals have been inked between the stakeholders engaged in antisense oligonucleotides market, highlighting the consolidation efforts of players engaged in the industry.

Question 7: What are the examples of some recently approved antisense oligonucleotide therapeutics?

Answer: Examples of recently approved antisense therapeutics include (in reverse chronological order) Viltepso™ (duchenne muscular dystrophy, March 2020), Vyondys 53® (duchenne muscular dystrophy, December 2019) and Waylivra® (hereditary transthyretin-mediated (hATTR) amyloidosis, May 2019).